This is an open label, randomized Phase II study to determine whether Mycophenolate mofetil
(MMF) given over 22 months meaningfully decreases the size of participants' HIV reservoir.
In addition to primary safety endpoints, the following hypotheses regarding drug efficacy
will be tested:
1. MMF will be well tolerated and will not decrease adherence to or antiviral efficacy of
ART.
2. Peripheral CD4+ T-cell counts and percentages will not meaningfully decrease during
treatment with MMF and ART.
3. There will be no excess risk of opportunistic infections in MMF-treated study
participants.
4. MMF therapy will lead to a progressive decrease in reservoir size over 22 months of
treatment.
5. MMF therapy will lead to a continual shift in HIV reservoir composition from primarily
effector memory CD4+ T cells (TEM) and central memory CD4+ T cells (TCM), to primarily
stem cell like memory (TSCM) and naïve (TN) CD4+ T cells.
6. MMF will eliminate detectable measures of the HIV reservoir, including by
cell-associated DNA/mRNA and quantitative viral outgrowth.
7. MMF will not decrease the humoral immune response to routine annual influenza
vaccination.